BEIJING (Reuters) - China's Stemirna Therapeutics said on Thursday it has raised nearly $200 million to finance clinical trials and production of its .
China's Stemirna Therapeutics said on Thursday it has raised nearly $200 million to finance clinical trials and production of its COVID-19 vaccine candidate.
Chinese Operator of Australia s Darwin Port Rejects Security Concerns - Landbridge executive insists 99-year lease is purely commercial after Canberra launches review